Macom Technology Solutions (MTSI) shares were up 3.6% in afternoon trading on Friday after BMO Capital upgraded the company's stock to outperform from market-perform.
Trading volume stood at more than 930,000 shares against a daily average of about 1.5 million.
Price: $272.63, Change: $+9.49, Percent Change: +3.61%
Loop Industries (LOOP) formed a committee to evaluate alternatives aimed at advancing commercialization and strengthening its capital position, including a broader project-financing structure for its planned India joint venture.The review will consider "strategic investments, project-level financing, licensing and commercial partnerships, regional joint ventures, business combinations, corporate-structure alternatives, a potential sale, merger or going-private transaction," the company said Thursday in a statement.Loop said there is no assurance the process will result in a sale, merger, going-private transaction or any other transaction or outcome.The review follows Jeff Geygan's appointment as chairman and the separation of the chairman and CEO roles, establishing a board-led process to evaluate capital needs and strategy.Loop shares rose 2% in after-hours trading.
Major digital assets rose Thursday, with Bitcoin (BTC-USD) topping the $76,000 level.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose 2% in the past 24 hours. The Nasdaq 100 rose 1.8%, the S&P 500 added 1.2%, and the Dow Jones Industrial Average increased 0.6%.Bitcoin gained 0.8% to $76,473, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume dropped 24.4% to $23.4 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, rose 1.8% to $2,445.XRP (XRP-USD) declined 0.3%, BNB (BNB-USD) rose 1.6%, and Solana (SOL-USD) gained 2.6%. Dogecoin (DOGE-USD) increased 1.5%, while Cardano (ADA-USD) advanced 3.7%.The total market value of the cryptocurrency industry rose 1.2% in the past 24 hours to $2.62 trillion, with trading volume dropping 12.6% to $77 billion.Price: $76600.00, Change: $+456.19, Percent Change: +0.60%
Ultragenyx Pharmaceutical (RARE) shares rose 11% after the company won FDA approval for Fayuvi, the first treatment for children with Sanfilippo syndrome type A, a rare genetic condition that progressively damages the brain and nervous system.Delivered as a one-time IV infusion, Fayuvi uses a modified virus to deliver a healthy gene, replacing the enzyme the patients lack. the FDA said Thursday in a statement. In clinical trials, treated children aged 2 to 5 maintained or improved their cognitive abilities compared to historical patient outcomes, the agency said.The FDA noted common side effects like fever, nausea, and elevated liver enzymes. The label also warns of potential long-term risks, including blood clotting issues and tumor formation, requiring patients to take immune-suppressing steroids around the time of treatment.Price: $14.34, Change: $+1.46, Percent Change: +11.34%